首页> 外文期刊>Clinical ophthalmology >Hypertensive phase and early complications after Ahmed glaucoma valve implantation with intraoperative subtenon triamcinolone acetonide
【24h】

Hypertensive phase and early complications after Ahmed glaucoma valve implantation with intraoperative subtenon triamcinolone acetonide

机译:艾哈迈德青光眼瓣膜植入术中亚氨曲安奈德术后高血压期及早期并发症

获取原文
       

摘要

Objective: To evaluate intraoperative subtenon triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma valve (AGV) implantation. Design: Retrospective comparative case series. Participants: Forty-two consecutive cases of uncontrolled glaucoma undergoing AGV implantation: 19?eyes receiving intraoperative subtenon TA and 23?eyes that did not receive TA.Methods: A retrospective chart review was performed on consecutive pseudophakic adult patients with uncontrolled glaucoma undergoing AGV with and without intraoperative subtenon TA injection by a single surgeon. Clinical data were collected from 42?eyes and analyzed for the first 6?months after surgery.Main outcome measures: Primary outcomes included intraocular pressure (IOP) and number of glaucoma medications prior to and after AGV implantation. The hypertensive phase (HP) was defined as an IOP measurement of greater than 21?mmHg (with or without medications) during the 6-month postoperative period that was not a result of tube obstruction, retraction, or malfunction. Postoperative complications and visual acuity were analyzed as secondary outcome measures. Results: Five out of 19?(26%) TA cases and 12?out of 23?(52%) non-TA cases developed the HP (P=0.027). Mean IOP (14.2±4.6?in TA cases versus [vs] 14.7±5.0?mmHg in non-TA cases; P=0.78), and number of glaucoma medications needed (1.8±1.3?in TA cases vs 1.6±1.1?in the comparison group; P=0.65) were similar between both groups at 6?months. Although rates of serious complications did not differ between the groups (13% in the TA group vs 16% in the non-TA group), early tube erosion (n=1) and bacterial endophthalmitis (n=1) were noted with TA but not in the non-TA group.Conclusions: Subtenon TA injection during AGV implantation may decrease the occurrence of the HP but does not alter the ultimate IOP outcome and may pose increased risk of serious complications within the first 6?months of surgery.
机译:目的:评估术中丙酮酸曲安奈德(TA)作为艾哈迈德青光眼瓣膜(AGV)植入术的辅助手段。设计:回顾性比较案例系列。参与者:连续42例接受AGV植入的不受控制的青光眼病例:19眼接受术中亚肌腱TA的手术和23眼未接受TA的方法。并且没有由一名外科医生进行术中亚腱下TA注射。临床数据收集自42眼,并在术后头6个月进行分析。主要预后指标:主要预后包括眼压(IOP)和AGV植入前后青光眼用药的数量。高血压期(HP)定义为术后6个月内的IOP值大于21?mmHg(有或没有药物),这不是管阻塞,收缩或功能障碍的结果。术后并发症和视敏度作为次要结局指标进行了分析。结果:19例(26%)TA患者中有5例,23例(52%)非TA患者中的12例出现了HP(P = 0.027)。平均IOP(TA患者为14.2±4.6?v,非TA患者为[vs] 14.7±5.0?mmHg; P = 0.78)和所需的青光眼用药数量(TA患者为1.8±1.3?v,而1.6±1.1?比较组; P = 0.65)在6个月时两组之间相似。尽管各组之间的严重并发症发生率没有差异(TA组为13%,非TA组为16%),但使用TA时可注意到早期管糜烂(n = 1)和细菌性眼​​内炎(n = 1),但结论:AGV植入过程中,亚腱TA注射可以减少HP的发生,但不会改变最终的IOP结局,并且可能在手术的前6个月内增加发生严重并发症的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号